- •Mistral Large 2512 argues HOLD because LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock has cleared the $1186.61 resistance barrier and is trading above the 4h resistance level of $1206.94, with rising RSI and a bullish MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
- •What changed: LLY cleared the $1186.61 resistance barrier and is now trading above the 4h resistance level of $1206.94. The FDA approval of Onswik (September 24, 2026) was announced, adding to the catalyst momentum. Technical indicators (RSI, MACD) remain bullish, and the Healthcare sector (XLV) is confirming the move.
LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock has cleared the $1186.61 resistance barrier and is trading above the 4h resistance level of $1206.94, with rising RSI and a bullish MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
The original thesis of a catalyst-driven swing toward $1220-$1250 remains intact. Price has broken above the $1186.61 resistance barrier that was the original premortem concern, and fresh catalysts (Onswik FDA approval, Foundayo adoption data) have reinforced the fundamental case. Momentum is accelerating with rising RSI and positive MACD, and the $1140 stop provides a well-defined risk boundary with 12 days remaining in the horizon.
LLY has already cleared the pivotal $1186.61 resistance named in the original thesis and holds above it with rising 4h RSI (62.68) and a positive/rising MACD, exactly the transmission path the entry anticipated. Fresh catalysts (Sep 24 Onswik FDA approval on top of Inluriyo/Verzenio and Mounjaro) keep the fundamental engine intact, and LLY's +3.28% session vs a flat-to-down SPY shows genuine relative strength with XLV confirmation. Stop at $1140 is untouched and target $1240 remains feasible via the LVN gap above $1206.
No model argued for EXIT.
- →Price fails to hold above the $1206.94 resistance level, reverses below $1185.88 support, and invalidates the breakout, closing the path to the original target.
Individual Model Review
LLY has already cleared the pivotal $1186.61 resistance named in the original thesis and holds above it with rising 4h RSI (62.68) and a positive/rising MACD, exactly the transmission path the entry anticipated. Fresh catalysts (Sep 24 Onswik FDA approval on top of Inluriyo/Verzenio and Mounjaro) keep the fundamental engine intact, and LLY's +3.28% session vs a flat-to-down SPY shows genuine relative strength with XLV confirmation. Stop at $1140 is untouched and target $1240 remains feasible via the LVN gap above $1206.
LLY has already cleared the pivotal $1186.61 resistance named in the original thesis and holds above it with rising 4h RSI (62.68) and a positive/rising MACD, exactly the transmission path the entry anticipated. Fresh catalysts (Sep 24 Onswik FDA approval on top of Inluriyo/Verzenio and Mounjaro) keep the fundamental engine intact, and LLY's +3.28% session vs a flat-to-down SPY shows genuine relative strength with XLV confirmation. Stop at $1140 is untouched and target $1240 remains feasible via the LVN gap above $1206.
▼ Click to expandThe broad regime flipped from calm/bullish to No Edge/bearish with narrowing breadth, and a dense HIGH-impact macro calendar (PCE, GDP, payrolls) lands Sep 30-Oct 2, raising the odds of a risk-off reversal. Price is stretched against the 4h upper Bollinger band right at the $1186-$1189 value-area edge, so a failed breakout back below support would invalidate the path to $1240.
▼ Click to expandThe original thesis of a catalyst-driven swing toward $1220-$1250 remains intact. Price has broken above the $1186.61 resistance barrier that was the original premortem concern, and fresh catalysts (Onswik FDA approval, Foundayo adoption data) have reinforced the fundamental case. Momentum is accelerating with rising RSI and positive MACD, and the $1140 stop provides a well-defined risk boundary with 12 days remaining in the horizon.
The original thesis of a catalyst-driven swing toward $1220-$1250 remains intact. Price has broken above the $1186.61 resistance barrier that was the original premortem concern, and fresh catalysts (Onswik FDA approval, Foundayo adoption data) have reinforced the fundamental case. Momentum is accelerating with rising RSI and positive MACD, and the $1140 stop provides a well-defined risk boundary with 12 days remaining in the horizon.
▼ Click to expandThe position is extended above the 4h upper Bollinger Band, and the broad market regime has shifted from bullish to bearish, which could cap upside. The $1206.94 4h resistance is the next barrier before the target, and a rejection there could trigger a pullback that invalidates the breakout. The risk/reward from current levels is tighter than at entry with only 4.3% to target versus 2.0% to the nearest support.
▼ Click to expandLLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock has cleared the $1186.61 resistance barrier and is trading above the 4h resistance level of $1206.94, with rising RSI and a bullish MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock has cleared the $1186.61 resistance barrier and is trading above the 4h resistance level of $1206.94, with rising RSI and a bullish MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
▼ Click to expandThe position could be threatened if LLY fails to hold above the $1206.94 resistance level and breaks below $1185.88 support, signaling a failed breakout. Broader market weakness, particularly in the Healthcare sector, or a reversal of recent catalysts could also undermine the thesis. If the stop at $1140 is breached, the risk/reward profile would deteriorate significantly.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on LLY. Verdict: HOLD (0/3 EXIT). Conviction: 77.